Browse studies

Find your next paid study

70 recruiting studies matching your filters

Topical Treatment for Atopic Dermatitis

Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to t…

Atopic Dermatitis

Estimated

~$10 – $750

Actual pay is set by the research site.

Wake Forest University Health SciencesNCT06244212

An Observational Study of Patients With Dermatologic Disease

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who tre…

VitiligoAtopic DermatitisAlopecia Areata+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Target PharmaSolutions, Inc.NCT07748169

Phase 1

Thera-Clean® Microbubbles System: A Pilot Study in Patients With Skin Diseases

Thera-Clean® Microbubble has proved to improve skin conditions in animals, however little research has been done regarding human subjects. Microbubble technolo…

Epidermolysis BullosaIchthyosisAtopic Dermatitis+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Northwestern UniversityNCT07050810

Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future researc…

Cutaneous T-cell LymphomaSezary SyndromeMycosis Fungoides+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of PittsburghNCT00177268

Phase 2

A Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (Aged 6 to 23 Months) With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled With Topical Therapy

The primary objective of the study is to assess the pharmacokinetics (PK) and safety of nemolizumab in pediatric participants (aged 6-23 months) with moderate-…

Moderate-to-Severe Atopic Dermatitis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Galderma R&DNCT07660835

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD)…

Atopic Dermatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Enveda TherapeuticsNCT07643766

Phase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of BxC-I17e Administered Subcutaneously in Patients With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderat…

Atopic Dermatitis

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Brexogen Inc.NCT06055361

Phase 2

A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema

This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX…

Eczema Atopic DermatitisEczemaAtopic Dermatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Turn TherapeuticsNCT07355075

Phase 3

A Phase 3, Multicenter, Long-Term, Open Label Study Evaluating the Safety and Efficacy of Abrocitinib, With or Without Topical Medications Administered to Pediatric Participants Aged 2 Years and Older With Moderate-to-Severe Atopic Dermatitis

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years…

Atopic Dermatitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

PfizerNCT06807281

CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring

The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking partic…

Atopic Dermatitis

Estimated

~$10 – $1,125

Actual pay is set by the research site.

PfizerNCT05721937